Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-Label Trial Using Velcade for ReTreatment of Multiple Myeloma Subjects Following an Initial Response to Velcade

NCT00431769 is registered in ClinicalTrials.gov with Janssen-Cilag International NV as lead sponsor.

NCT NCT00431769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00431769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-Label Trial Using Velcade for ReTreatment of Multiple Myeloma Subjects Following an Initial Response to Velcade
Lead sponsor
Janssen-Cilag International NV
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2006
Completion date
January 31, 2010
Enrollment
130 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma